Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (3997)	11/28/2015 6:20:57 PM
From: tktom	Respond to of 4474

It is remarkable that we were able to command milestone payments from a Big Pharma company, which is indicative of Otsuka’s interest in and commitment to Iclusig®. It is a vote of confidence in us.In addition to this unique business model, what are ARIAD’s other strengths? There are three main features of ARIAD I would like to highlight. Firstly, as our model demonstrates, we are very focused on academic rigor and the quality of our scientific research. Haematology is intrinsically one of the most academic areas in medicine and pharmaceuticals, and we are expressly dedicated to the pursuit of quality academic results. This guarantees the effectiveness of our therapies "It is remarkable that we were able to command milestone payments from a Big Pharma company, which is indicative of Otsuka’s interest in and commitment to Iclusig®" - Gee, I'm just not sure that is "remarkable". "This guarantees the effectiveness of our therapies."- Sounds like a salesman and not a scientist.